| P50 | author | Hazel Rogers | Q57416591 |
| | Richard G Grundy | Q58068549 |
| P2093 | author name string | Jasper Estranero | |
| | Keshni Gudka | |
| P2860 | cites work | PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. | Q55469269 |
| | Mutations of PIK3CA in Anaplastic Oligodendrogliomas, High-Grade Astrocytomas, and Medulloblastomas | Q57293479 |
| | Childhood central nervous system tumours--incidence and survival in Europe (1978-1997): report from Automated Childhood Cancer Information System project. | Q61625484 |
| | Detection of genetic and chromosomal aberrations in medulloblastomas and primitive neuroectodermal tumors with DNA microarrays | Q80237000 |
| | Amplification and overexpression of KIT, PDGFRA, and VEGFR2 in medulloblastomas and primitive neuroectodermal tumors | Q43271629 |
| | Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. | Q44314802 |
| | Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3'-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. | Q44679897 |
| | A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG). | Q46088442 |
| | Phase I study of everolimus in pediatric patients with refractory solid tumors | Q46942053 |
| | The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas | Q47605452 |
| | Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. | Q48221611 |
| | Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort | Q48258630 |
| | Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets | Q48315065 |
| | Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue. | Q48460429 |
| | Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma | Q48761873 |
| | Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy | Q21198871 |
| | Pushing the envelope in the mTOR pathway: the second generation of inhibitors | Q24622222 |
| | mTOR: from growth signal integration to cancer, diabetes and ageing | Q24633662 |
| | An integrated genomic analysis of human glioblastoma multiforme | Q24648860 |
| | What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway | Q26825780 |
| | Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma | Q26865645 |
| | PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer | Q27860985 |
| | TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling | Q28131740 |
| | High frequency of mutations of the PIK3CA gene in human cancers | Q28131776 |
| | Signaling by distinct classes of phosphoinositide 3-kinases | Q28139034 |
| | Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer | Q28241808 |
| | Current development of mTOR inhibitors as anticancer agents | Q28255366 |
| | Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas | Q28299301 |
| | The genetic landscape of the childhood cancer medulloblastoma | Q28301196 |
| | Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis and immunotherapy | Q29248893 |
| | ras oncogenes in human cancer: a review | Q29547769 |
| | Targeting the phosphoinositide 3-kinase pathway in cancer | Q29615809 |
| | Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial | Q29618031 |
| | RAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms | Q33289438 |
| | Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma | Q33397833 |
| | Novel role for insulin as an autocrine growth factor for malignant brain tumour cells | Q40132300 |
| | Phosphatidylinositol 3'-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN. | Q40278543 |
| | Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. | Q42282551 |
| | Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth | Q43211413 |
| | A multicenter, first-in-pediatrics, phase 1, pharmacokinetic and pharmacodynamic study of ridaforolimus in patients with refractory solid tumors | Q33407568 |
| | Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study | Q33411585 |
| | A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report | Q33419115 |
| | A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors | Q33435808 |
| | Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS. | Q33716552 |
| | The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma | Q33751426 |
| | A sensitized RNA interference screen identifies a novel role for the PI3K p110γ isoform in medulloblastoma cell proliferation and chemoresistance. | Q33926416 |
| | Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease | Q33990951 |
| | Cross-species genomics matches driver mutations and cell compartments to model ependymoma | Q34031780 |
| | Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma | Q34129360 |
| | ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. | Q34153957 |
| | CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity | Q34157312 |
| | Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas | Q34167499 |
| | Protein expression of platelet-derived growth factor receptor correlates with malignant histology and PTEN with survival in childhood gliomas | Q34191508 |
| | Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children's Oncology Group | Q34196216 |
| | Epigenomic alterations define lethal CIMP-positive ependymomas of infancy | Q34240198 |
| | Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program. | Q34249719 |
| | Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma | Q34442835 |
| | Phenotypic variations in NF1-associated low grade astrocytomas: possible role for increased mTOR activation in a subset | Q34467227 |
| | A prognostic analysis of pediatrics central nervous system small cell tumors: evaluation of EGFR family gene amplification and overexpression | Q34486255 |
| | Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib | Q34572719 |
| | Childhood brain tumors | Q34573495 |
| | Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program | Q34592429 |
| | Establishment and characterization of clinically relevant models of ependymoma: a true challenge for targeted therapy | Q35085321 |
| | Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors | Q35112340 |
| | An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. | Q35212577 |
| | PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting | Q35260766 |
| | A phase I trial of MK-2206 in children with refractory malignancies: a Children's Oncology Group study | Q35684517 |
| | Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist | Q35718965 |
| | An in vivo screen identifies ependymoma oncogenes and tumor-suppressor genes. | Q35904519 |
| | PI3K/AKT pathway alterations are associated with clinically aggressive and histologically anaplastic subsets of pilocytic astrocytoma | Q36157714 |
| | PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome | Q36179171 |
| | PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex. | Q36244792 |
| | Atypical teratoid/rhabdoid tumors of the central nervous system | Q36272994 |
| | Predictors of outcome in an AIEOP series of childhood ependymomas: a multifactorial analysis | Q36344765 |
| | Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program. | Q36386881 |
| | Pediatric glioma-associated KIAA1549:BRAF expression regulates neuroglial cell growth in a cell type-specific and mTOR-dependent manner. | Q36464991 |
| | BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas | Q36532504 |
| | Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma | Q36774588 |
| | A new mutational AKTivation in the PI3K pathway | Q36907930 |
| | Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas | Q37055286 |
| | The regulation and function of Class III PI3Ks: novel roles for Vps34. | Q37063618 |
| | An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer | Q37187915 |
| | Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas | Q37238690 |
| | p87 and p101 subunits are distinct regulators determining class IB phosphoinositide 3-kinase (PI3K) specificity | Q37312165 |
| | Activation of mTORC1/mTORC2 signaling in pediatric low-grade glioma and pilocytic astrocytoma reveals mTOR as a therapeutic target | Q37312742 |
| | Perifosine: update on a novel Akt inhibitor. | Q37393008 |
| | Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature | Q37399421 |
| | Medulloblastomics: the end of the beginning | Q37469904 |
| | Regulation and cellular functions of class II phosphoinositide 3-kinases. | Q38002953 |
| | PI3K in cancer-stroma interactions: bad in seed and ugly in soil. | Q38124762 |
| | Subependymal giant cell astrocytomas in patients with tuberous sclerosis complex: considerations for surgical or pharmacotherapeutic intervention | Q38150748 |
| | Targeted therapy in pediatric low-grade glioma | Q38194055 |
| | Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours | Q38392521 |
| | EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines | Q38420153 |
| | Drugging PI3K in cancer: refining targets and therapeutic strategies | Q38539217 |
| | Tuberous sclerosis--A model for tumour growth | Q38713439 |
| | JPO2/CDCA7L and LEDGF/p75 Are Novel Mediators of PI3K/AKT Signaling and Aggressive Phenotypes in Medulloblastoma | Q38783253 |
| | The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary | Q38829244 |
| | Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus. | Q38905340 |
| | The PI3K inhibitor GDC-0941 displays promising in vitro and in vivo efficacy for targeted medulloblastoma therapy | Q38919020 |
| | A novel C19MC amplified cell line links Lin28/let-7 to mTOR signaling in embryonal tumor with multilayered rosettes | Q39047678 |
| | PI3K pathway activation provides a novel therapeutic target for pediatric ependymoma and is an independent marker of progression-free survival | Q39090163 |
| | TSC1 involvement in bladder cancer: diverse effects and therapeutic implications | Q39196241 |
| | Targeting PI3KC2β impairs proliferation and survival in acute leukemia, brain tumours and neuroendocrine tumours | Q39306427 |
| | Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors | Q39365297 |
| | The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia | Q39722770 |
| | Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration. | Q39922005 |
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | brain tumor | Q233309 |
| | targeted therapy | Q492646 |
| | phosphoinositide-3 kinase inhibitor | Q7187512 |
| | protein kinase inhibitors | Q7251487 |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 2083-2095 | |
| P577 | publication date | 2016-12-02 | |
| | 2017-01-10 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors | |
| P478 | volume | 8 | |